@article{5817c7a44ce14f93b80ccb5dc105ff1c,
title = "Risankizumab Is Effective for The Management of Crohn{\textquoteright}s Disease of the Pouch",
abstract = "In this prospective, multicenter observational study of highly refractory patients with Crohn{\textquoteright}s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50\% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8\% at 12 weeks.",
author = "Maia Kayal and Spencer, \{Elizabeth A.\} and Matthew Smyth and Laura Raffals and Taha Qazi and Parakkal Deepak and Poonam Beniwal-Patel and Shannon Chang and Peter Higgins and Cross, \{Raymond K.\} and Chelsea Anderson and Millie Long and Herfarth, \{Hans H.\} and Dubinsky, \{Marla C.\} and Barnes, \{Edward L.\}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of Crohn{\textquoteright}s \& Colitis Foundation. All rights reserved.",
year = "2025",
month = mar,
day = "1",
doi = "10.1093/ibd/izae164",
language = "English",
volume = "31",
pages = "878--881",
journal = "Inflammatory bowel diseases",
issn = "1078-0998",
number = "3",
}